Literature DB >> 727045

Radioimmunoassay of prostaglandins and thromboxanes.

E Granström, H Kindahl.   

Abstract

1. Decide on what organ or other biological material to study and select the proper compound for this study from the knowledge of precursor acid metabolism. Develop the RIA for this compound or a stable derivative thereof. 2. Whichever sample type is assayed (extracted or unextracted), the possibility of the presence of nonspecific interfering factors must be constantly kept in mind. Make dilution tests and assay for parallelism; however, do not accept parallelism as an absolute criterion of absence of nonspecific influence. 3. Use two or more completely different separation techniques for comparison when validating the RIA. 4. When evaluating the RIA, do not limit the investigation to the traditional reliability criteria: sensitivity, specificity, precision, and accuracy. The RIA may seem reliable at this stage and still give completely unrealistic values when applied to biological material. The method must be evaluated by other studies as well. 5. In the experimental design, aim at following the changes in prostaglandin levels in a series of samples instead of measuring absolute levels in single samples. 6. Make comparative studies employing different quantitative methods.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 727045

Source DB:  PubMed          Journal:  Adv Prostaglandin Thromboxane Res        ISSN: 0361-5952


  29 in total

1.  Treatment with LPS plus INF-γ induces the expression and function of muscarinic acetylcholine receptors, modulating NIH3T3 cell proliferation: participation of NOS and COX.

Authors:  A J Español; M O Maddaleno; M G Lombardi; M Cella; P Martínez Pulido; M E Sales
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

2.  15-Hydroxy-5,8,11,13-eicosatetraenoic acid inhibits human vascular cyclooxygenase. Potential role in diabetic vascular disease.

Authors:  B N Setty; M J Stuart
Journal:  J Clin Invest       Date:  1986-01       Impact factor: 14.808

3.  In vitro prostanoid release from spinal cord following peripheral inflammation: effects of substance P, NMDA and capsaicin.

Authors:  D M Dirig; T L Yaksh
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

4.  Prostaglandins and thromboxane in the delayed phase of shock induced by Serratia marcescens endotoxin.

Authors:  J R Parratt; N Sharma; I J Zeitlin
Journal:  Br J Pharmacol       Date:  1984-05       Impact factor: 8.739

5.  The effect of medium and long chain triglyceride on human adipose tissue metabolism.

Authors:  D P Katz; J L Knittle
Journal:  Lipids       Date:  1987-06       Impact factor: 1.880

6.  Effect of baclofen on different models of bronchial hyperreactivity in the guinea-pig.

Authors:  S Luzzi; S Franchi-Micheli; G Folco; G Rossoni; M Ciuffi; L Zilletti
Journal:  Agents Actions       Date:  1987-04

7.  Equine postanaesthetic myositis: thromboxanes, prostacyclin and prostaglandin E2 production.

Authors:  D Serteyn; G Deby-Dupont; J Pincemail; E Mottart; C Philippart; M Lamy
Journal:  Vet Res Commun       Date:  1988       Impact factor: 2.459

8.  Effect of tienoxolol, a new diuretic beta-blocking agent, on urinary prostaglandin excretion in the rat.

Authors:  F Caussade; A Cloarec
Journal:  Br J Pharmacol       Date:  1993-05       Impact factor: 8.739

9.  Arachidonic acid and prostaglandin endoperoxide metabolism in isolated rabbit and coronary microvessels and isolated and cultivated coronary microvessel endothelial cells.

Authors:  M E Gerritsen; C D Cheli
Journal:  J Clin Invest       Date:  1983-11       Impact factor: 14.808

10.  The effects of bicarbonate and acetate haemodialysis on platelet cyclic AMP concentration, thromboxane B2 release and aggregation.

Authors:  S Túri; C Bereczki; C Torday; Z Havass; M Németh
Journal:  Pediatr Nephrol       Date:  1991-05       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.